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Is C0 better than C2 as a
determinant of rejection in
renal transplant recipients?
To the Editor: During the past years C2 monitor-
ing of cyclosporine microemulsion (CsA) has been fo-
cused on as a new, improved, and possibly more “cor-
rect” monitoring regimen in transplant recipients [1–3].
I read with great interest the publication by Perico et al
[4] in Kidney International. They concluded that among
serial daily CsA measurements post-transplant, a CsA
trough blood concentration of 300 to 440 ng/mL (and
not C2) taken as early as day 2 has by far the high-
est capacity to predict rejection episodes. These results
diverge from most recent publications. I register, how-
ever, that it is not stated in the text or in the tables or
figures how many patients that were actually included
in their final analysis. When reading the article, one
gets the impression that 224 patients (334 patients mi-
nus 110 patients with delayed graft function) were in-
cluded. From Table 3, which only includes data from
16 patients, one can calculate that the total material an-
alyzed seems to be from only 39 patients [group below:
10 patients = 76.9% (i.e., 13 patients = 100%); group
within:1 patient = 14.2% (i.e., 7 patients = 100%); group
above: 5 patients = 26.3% (i.e., 19 patients = 100%)]. This
is definitely not clear in the text and dramatically lowers
the quality of the study. In Table 2, patients with no rejec-
tion have a C0 of 539 ± 250 ng/mL compared to patients
with rejection having a C0 of 335 ± 248 ng/mL (N = 39?).
How one can conclude from these data that a C0 on day
2 between 300 to 440 ng/mL is the best predictor needs
to be explained.
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About the mechanisms of
renoprotective effect of
angiotensin inhibitors on lupus
nephritis
To the Editor: We read with interest the paper by Alves
de Albuquerque et al [1] reporting on beneficial effects
of angiotensin-converting enzyme (ACE) inhibitor treat-
ment on the development of nephritis in NZBxNZW F1
and MRL/lpr mice. They showed that captopril treat-
ment decreased transforming growth factor-b1 (TGF-
b1) and TGF-b2 expression, and postulated effects of
ACE inhibition on immunologic parameters. We recently
reported on the beneficial effects of treatment with ei-
ther ACE inhibitor (enalapril) or angiotensin receptor
antagonist (candesartan) on nephritis development in
MRL/lpr mice [2]. In spite of comparable anti-DNA anti-
body titers and glomerular immune complex deposition,
proteinuria and histology were markedly ameliorated
by either treatment, and the decreased inflammatory
cell infiltrate was associated with decreased renal ex-
pression of chemokines such as CCL4 and CCL2. These
effects cannot be directly related to decreased TGF-b
expression, as TGF-b is known to inhibit chemokine ex-
pression, and thus, lowered TGF-b would result in in-
creased chemokine expression [3]. Similar to Alves de
Albuquerque et al, our data also indicate effects of an-
giotensin on the local, intrarenal inflammatory process,
but most likely on steps influencing inflammatory cell
infiltrates. The reduced TGF-b expression observed by
Alves de Albuquerque et al might then be a result of
decreased cell infiltration, and further influence down-
stream processes. Taken together, our results also sup-
port an immune modulatory role for angiotensin in the
course of murine lupus nephritis.
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